((自动化翻译由路透提供，请见免责声明 )) (在第 2 至第 5 段中增加了详细信息)
路透1月13日 - 礼来 周一表示，将以最高25亿美元的现金收购癌症疗法开发商Scorpion Therapeutics。
礼来将收购Scorpion的实验性口服疗法STX-478，该疗法目前正在进行乳腺癌和其他晚期实体瘤的早期试验。
该疗法是一种 PI3K 抑制剂，可选择性地靶向一种名为 PI3K 的蛋白质。
协议包括预付款和在达到某些监管和销售里程碑后的后续付款。
作为交易的一部分，Scorpion 将分拆出一个新实体，以持有其员工和非 PI3K 管线资产。这家独立的新公司将由 Scorpion 目前的股东拥有，礼来持有少数股权。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.